Skip to main content
Signal8

enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study

$NVNOPress releaseOct 30, 2026, 8:30 AM ETRead the release

enVVeno Medical reported a Q3 2026 net loss of $4.4 million ($6.29 per share) and ended the quarter with $18.5 million in cash and investments, with quarterly burn of roughly $3 million. The company is on track to treat the first patients in the FDA-approved TAVVE pivotal study of its enVVe venous valve before year end, starting with a 10-patient safety stage before a 220-patient randomized stage.

Key figures

Guidance
Cash burn expected to rise to $4M-$5M per quarter in H1 2027 as TAVVE enrolls
Net loss
$4.4 million
Cash runway
into Q4 2027
Operating expenses
$4.5 million
Quarterly cash burn
$3 million
Cash and investments
$18.5 million

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.